A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity

Peptides derived from the C-terminal heptad repeat (CHR) region of the human immunodeficiency virus type 1 (HIV-1) fusogenic protein gp41 are potent viral entry inhibitors, and currently, enfuvirtide (T-20) is the only one approved for clinical use; however, emerging drug resistance largely limits i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Virol
Hlavní autoři: Chong, Huihui, Xue, Jing, Xiong, Shengwen, Cong, Zhe, Ding, Xiaohui, Zhu, Yuanmei, Liu, Zixuan, Chen, Ting, Feng, Yifan, He, Lei, Guo, Yan, Wei, Qiang, Zhou, Yusen, Qin, Chuan, He, Yuxian
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2017
Témata:
Vaccines and Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5432875/
https://ncbi.nlm.nih.gov/pubmed/28356533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00288-17
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky